Success Metrics

Clinical Success Rate
81.3%

Based on 13 completed trials

Completion Rate
81%(13/16)
Active Trials
2(10%)
Results Posted
92%(12 trials)
Terminated
3(15%)

Phase Distribution

Ph phase_2
8
40%
Ph phase_3
2
10%
Ph phase_4
1
5%
Ph phase_1
8
40%

Phase Distribution

8

Early Stage

8

Mid Stage

3

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
8(42.1%)
Phase 2Efficacy & side effects
8(42.1%)
Phase 3Large-scale testing
2(10.5%)
Phase 4Post-market surveillance
1(5.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.5%

13 of 17 finished

Non-Completion Rate

23.5%

4 ended early

Currently Active

2

trials recruiting

Total Trials

20

all time

Status Distribution
Active(2)
Completed(13)
Terminated(4)
Other(1)

Detailed Status

Completed13
Terminated3
unknown1
Withdrawn1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
2
Success Rate
81.3%
Most Advanced
Phase 4

Trials by Phase

Phase 18 (42.1%)
Phase 28 (42.1%)
Phase 32 (10.5%)
Phase 41 (5.3%)

Trials by Status

unknown15%
withdrawn15%
completed1365%
recruiting15%
active_not_recruiting15%
terminated315%

Recent Activity

2 active trials
Showing 5 of 20
completedphase_3

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

NCT02881086
active_not_recruitingphase_2

A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

NCT01920737
completedphase_2

ALL Adult Consortium Trial: Adult ALL Trial

NCT00476190
completedphase_1

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT02303821
completedphase_2

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT03384654
View all 20 trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT02881086Phase 3

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Completed
NCT01920737Phase 2

A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT00476190Phase 2

ALL Adult Consortium Trial: Adult ALL Trial

Completed
NCT02303821Phase 1

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed
NCT03384654Phase 2

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed
NCT05959720

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

Recruiting
NCT01523977Phase 1

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

Completed
NCT02393859Phase 3

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Completed
NCT01186328Phase 1

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Terminated
NCT03349281Phase 1

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

Completed
NCT01451515Phase 2

NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Completed
NCT00439296Phase 1

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

Terminated
NCT00440726Phase 1

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

Completed
NCT00866749Phase 2

Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

Completed
NCT02518750Phase 2

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Terminated
NCT01769209Phase 2

Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed
NCT01324180Phase 1

Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

Completed
NCT00973752Phase 2

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Completed
NCT00957320Phase 1

Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)

Withdrawn
NCT00192673Phase 4

Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses

Unknown

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20